TA
XERS icon

Tamarack Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

Tamarack Advisers’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-350,000
Closed -$1.58M – 77
2021
Q1 		$1.58M Buy
+350,000
New +$1.89M 0.32% 40

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers's XERS Position: Q2 2021 in Review

Tamarack Advisers sold out of Xeris Biopharma Holdings (XERS) in Q2 2021, closing a stake of 350,000 shares — an estimated $1.58M sold.

Tamarack Advisers first reported a position in XERS in Q1 2021 and held it in 1 quarter. The position peaked at $1.58M in Q1 2021. 93 funds tracked by Wall St. Rank hold XERS as of Q2 2021.

  • Tamarack Advisers reported no remaining Xeris Biopharma Holdings position as of Q2 2021 after selling out during the quarter.
  • Tamarack Advisers sold 350,000 Xeris Biopharma Holdings shares in Q2 2021, an estimated $1.58M.
  • Tamarack Advisers first reported a position in Xeris Biopharma Holdings in Q1 2021 and held it in 1 quarter.
  • Tamarack Advisers's Xeris Biopharma Holdings position peaked at $1.58M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2021.

Based on Tamarack Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.